Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Withers, Barbara  [Clear All Filters]
Journal Article
Othman J, Greenwood M, Moore J, Larsen S, Watson A-M, Arthur C, Bhattacharyya A, Bilmon I, Blyth E, Bryant A, et al. Unrelated donor transplant recipients given Thymoglobuline have superior GRFS when compared to matched related donor recipients transplanted without ATG. Biol Blood Marrow Transplant. 2020.
Withers B, Clancy L, Burgess J, Simms R, Brown R, Micklethwaite K, Blyth E, Gottlieb D. Establishment and operation of a third party virus-specific T-cell bank within an allogeneic stem cell transplant program. Biol Blood Marrow Transplant. 2018.
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Havrdova EKubala, et al. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024.
Massey J, Artuz C, Dyer Z, Jackson K, Khoo M, Visweswaran M, Withers B, Moore J, Ma D, Sutton I. Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis. Clin Immunol. 2023:109709.
Massey J, Visweswaran M, Khoo M, Hendrawan K, Sutton I, Withers B, Ma D, Moore J. Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant. Cytotherapy. 2023.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, et al. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2023;80(7):702-713.
Blyth E, Withers B, Clancy L, Gottlieb D. CMV-specific immune reconstitution following allogeneic stem cell transplantation. Virulence. 2016:1-14.